We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients

By LabMedica International staff writers
Posted on 01 Nov 2025

Lupus is an autoimmune disorder that causes the immune system to attack the body’s own tissues and organs. More...

Among the five million people living with lupus globally, nearly half develop lupus nephritis, a severe kidney inflammation that is a leading cause of death. Between 5% and 25% of patients with lupus nephritis die from kidney-related complications within five years of onset. Currently, monitoring kidney health relies on renal biopsies—painful, invasive procedures with risks of bleeding and infection, as well as subjectivity in interpretation. Now, monitoring kidney damage in lupus patients may soon become far less invasive.

A new study from the University of Houston (Houston, TX, USA) has found that urine samples can reveal the severity and progression of lupus nephritis—a major complication of systemic lupus erythematosus (SLE)—without requiring repeat renal biopsies. The discovery could transform disease management for millions worldwide. The new study aimed to identify noninvasive biomarkers capable of predicting kidney inflammation and scarring by analyzing urinary proteins through a large-scale proteomics approach.

Using 1,317 urine samples collected at the time of biopsy from patients with lupus nephritis, the researchers identified 57 proteins that were significantly elevated in individuals whose kidney tissue showed active damage. These elevated proteins were linked to microscopic signs such as vascular swelling, tissue necrosis, and clusters of injured cells—hallmarks of ongoing inflammation.

Further analysis revealed that some urinary proteins were also associated with chronic scarring, suggesting they could help clinicians distinguish between active disease and long-term damage. These findings, published in The Journal of Clinical Investigation, demonstrate that urine-based biomarkers could provide a reliable, repeatable, and noninvasive way to assess kidney disease activity and progression in lupus patients.

“Overall, the results indicate that by measuring certain proteins in urine, doctors might be able to tell how active or long-lasting someone’s lupus-related kidney disease is, and they could check kidney health without having to do another biopsy,” said Dr. Chandra Mohan, an international expert and pioneer in lupus research at the University of Houston.

Related Links:
University of Houston


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Noul’s AI-based cervical cancer diagnostic solution, miLab CER (Photo courtesy of Noul)

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.